The Epilepsy-Desirability of Outcome Ranking (DOOR) as a Multi-Faceted Consumer-Informed Outcome Measure for Epilepsy Clinical Trials.

Eur J Neurol · 2026 · PMC12888095 · PMID 41665255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The 20 mg group had a higher responder rate (odds ratio 2.13, 95% CI 0.96, 4.69) and % change in seizure frequency over placebo (win odds 1.30, 95% CI 0.98, 1.73) which did not reach statistical significance; however, adverse events were worse than placebo in the 20 mg group (win odds 0.69, 95% CI 0.51, 0.94) and thus the Epilepsy‐DOOR showed no benefit over placebo (win odds 0.98, 95% CI 0.71, 1.35).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.